Form 4: Allogene Therapeutics Director Franz Humer Awarded 95,400 Restricted Stock Units

Allogene Therapeutics, Inc. Director Franz B. Humer was granted 95,400 Restricted Stock Units (RSUs) on June 18, 2025, as part of his compensation.

Summary

• Franz B. Humer, a Director of Allogene Therapeutics, Inc. (ALLO), was awarded 95,400 Restricted Stock Units (RSUs).
• The transaction date for this grant was June 18, 2025.
• Each RSU represents a contingent right to receive one share of the company's Common Stock.
• The RSUs will vest in two successive equal semi-annual installments over a one-year period, measured from the grant date.
• Vesting is contingent upon Mr. Humer's continued service through each vesting date.
• Mr. Humer has elected to defer the receipt of Common Stock upon the vesting of his RSUs.
• The deferral is pursuant to the Company's Non-Employee Director Compensation Policy.
• Receipt of the deferred shares will occur at the earlier of 30 days following separation from the Board or a change in control of the Company.

Sentiment

Score: 7

Explanation: The RSU grant is a positive event, indicating continued director commitment and aligning interests with shareholders, which is generally viewed favorably.

Positives

• The grant of Restricted Stock Units to a director aligns their long-term interests with those of the shareholders, incentivizing continued performance and commitment.
• The deferral election by Mr. Humer, pursuant to company policy, demonstrates a long-term perspective and adherence to corporate governance frameworks.

Future Outlook

The 95,400 Restricted Stock Units granted to Director Franz B. Humer are scheduled to vest in two equal semi-annual installments over a one-year period from the grant date, subject to his continued service. The actual receipt of shares will be deferred until his separation from the Board or a change in control.

Management Comments

• Mr. Humer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Company's Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company.

Industry Context

This RSU grant is a standard form of equity compensation for non-employee directors in the biotechnology and pharmaceutical industry, designed to align their interests with long-term shareholder value.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs represents potential future dilution upon vesting and conversion to common stock, but also serves to align the director's interests with long-term shareholder value.
• Director (Franz B. Humer): Receives equity compensation that incentivizes continued service and performance, with a deferral option for tax or personal planning.

Next Steps

• The Restricted Stock Units will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant.
• Mr. Humer will receive the Common Stock from the vested RSUs upon the earlier of 30 days following his separation from the Board or a change in control of the Company.

Key Dates

Keywords

Allogene Therapeutics, ALLO, Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Corporate Governance